A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

NCT06644781 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

510

Enrollment

INDUSTRY

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Ifinatamab deruxtecan
DRUG: Docetaxel
DRUG: Paclitaxel
DRUG: Irinotecan hydrochloride (HCl)

Sponsor

Daiichi Sankyo

Collaborators

[object Object]